Evidence map›Paper›PMID 21365257›Full record

ReviewStem cell reviews and reports2011

A comparison of stem cells for therapeutic use.

Denis O Rodgerson, Alan G Harris

Erratum issuedAbstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Bridging Stem Cell Research from Humans to Animals.Journal of veterinary science & medical diagnosis · 2012
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

2 authors.

Denis O RodgersonNeoStem, Inc., 420 Lexington Avenue, Suite 450, New York, NY 10170, USA. drodgerson@neostem.com
Alan G Harris

Funding

Repair of boney defects by human stem cellsR43AR056893 · NIAMS · LISATA THERAPEUTICS INC · PI RODGERSON, DENIS OVEREND, TAICHMAN, RUSSELL S · 2009 to 2009
$109k
NIAMS NIH HHS R43 AR056893-01A1
6 · The paper itself

Abstract

A critical comparison of the attributes of several types of stem cells is presented, with particular emphasis on properties that are critical for the application of these cells for therapeutic purposes. The importance of an autologous source of pluripotent stem cells is stressed. It is apparent that two sources currently exist for non-embryonic pluripotent stem cells--very small embryonic-like stem cells (VSELs) and induced pluripotent stem cells (iPS). The impact of the emerging iPS research on therapy is considered.

Indexed as

RegenerationAnimalsCell Culture TechniquesCell DifferentiationCell MovementEmbryonic Stem CellsEpigenesis, GeneticGenetic MarkersHematopoietic Stem CellsHumansInduced Pluripotent Stem CellsMiceStem Cell ResearchStem Cell TransplantationGenetic Markers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.